<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmcpsychiatry&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Psychiatry - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmcpsychiatry/</link>
        <description>The latest research articles published by BMC Psychiatry</description>
        <dc:date>2009-07-09T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/42" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/41" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/40" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/39" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/38" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/37" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/36" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/35" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/34" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-244X/9/33" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/42">
        <title>The Brief Fear of Negative Evaluation Scale (BFNE): translation and validation study of the Iranian version</title>
        <description>Background:
The Brief Fear of Negative Evaluation Scale (BFNE) is a commonly used instrument to measure social anxiety. This study aimed to translate and to test the reliability and validity of the BFNE in Iran.
Methods:
The English language version of the BFNE was translated into Persian (Iranian language) and was used in this study. The questionnaire was administered to a consecutive sample of 235 students with (n = 33, clinical group) and without social phobia (n = 202, non-clinical group). In addition to the BFNE, two standard instruments were used to measure social phobia severity: the Social Phobia Inventory (SPIN), and the Social Interaction Anxiety Scale (SIAS). All participants completed a brief background information questionnaire, the SPIN, the SIAS and the BFNE scales. Statistical analysis was performed to test the reliability and validity of the BFNE.
Results:
In all 235 students were studied (111 male and 124 female). The mean age for non-clinical group was 22.2 (SD = 2.1) years and for clinical sample it was 22.4 (SD = 1.8) years. Cronbach&apos;s alpha coefficient (to test reliability) was acceptable for both non-clinical and clinical samples (a = 0.90 and 0.82 respectively). In addition, 3-week test-retest reliability was performed in non-clinical sample and the intraclass correlation coefficient (ICC) was quite high (ICC = 0.71). Validity as performed using convergent and discriminant validity showed satisfactory results. The questionnaire correlated well with established measures of social phobia such as the SPIN (r =0.43, p &lt; 0.001) and the SIAS (r =0.54, p &lt;0.001). Also the BFNE discriminated well between men and women with and without social phobia in the expected direction. Factor analysis supported a two-factor solution corresponding to positive and reverse-worded items.
Conclusion:
This validation study of the Iranian version of BFNE proved that it is an acceptable, reliable and valid measure of social phobia. However, since the scale showed a two-factor structure and this does not confirm to the theoretical basis for the BFNE, thus we suggest the use of the BFNE-II when it becomes available in Iran. The validation study of the BFNE-II is in progress.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/42</link>
                <dc:creator>Azadeh Tavoli</dc:creator>
                <dc:creator>Mahdiyeh Melyani</dc:creator>
                <dc:creator>Maryam Bakhtiari</dc:creator>
                <dc:creator>Gholam Hossien Ghaedi</dc:creator>
                <dc:creator>Ali Montazeri</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:42</dc:source>
        <dc:date>2009-07-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-42</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2009-07-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/41">
        <title>The effects of crisis plans for patients with psychotic and bipolar disorders: a randomised controlled trial</title>
        <description>Background:
Crises and (involuntary) admissions have a strong impact on patients and their caregivers. In some countries, including the Netherlands, the numbers of crises and (involuntary) admissions have increased in the last years. There is also a lack of effective interventions to prevent their occurrence. Previous research has shown that a form of psychiatric advance statement - joint crisis plans - may prevent involuntary admissions, but another study showed no significant results for another form. The question remains which form of psychiatric advance statement may help to prevent crisis situations. This study examines the effects of two other psychiatric advance statements. The first is created by the patient with help from a patient&apos;s advocate (Patient Advocate Crisis Plan: PACP) and the second with the help of a clinician only (Clinician facilitated Crisis Plan: CCP). We investigate whether patients with a PACP or CCP show fewer emergency visits and (involuntary) admissions as compared to patients without a psychiatric advance statement. Furthermore, this study seeks to identify possible mechanisms responsible for the effects of a PACP or a CCP.
Methods:
This study is a randomised controlled trial with two intervention groups and one control condition. Both interventions consist of a crisis plan, facilitated through the patient&apos;s advocate or the clinician respectively.Outpatients with psychotic or bipolar disorders, who experienced at least one psychiatric crisis during the previous two years, are randomly allocated to one of the three groups. Primary outcomes are the number of emergency (after hour) visits, (involuntary) admissions and the length of stay in hospital. Secondary outcomes include psychosocial functioning and treatment satisfaction. The possible mediator variables of the effects of the crisis plans are investigated by assessing the patient&apos;s involvement in the creation of the crisis plan, working alliance, insight into illness, recovery style, social support, locus of control, service engagement and coping with crises situations. The interviews take place before randomisation, nine month later and finally eighteen months after randomisation.DiscussionThis study examines the effects of two types of crisis plans. In addition, the results offer an understanding of the way these advance statements work and whether it is more effective to include a patients&apos; advocate in the process of creating a psychiatric advance statement. These statements may be an intervention to prevent crises and the use of compulsion in mental health care. The strength and limitations of this study are discussed.Trial registration: Current Controlled Trails NTR1166.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/41</link>
                <dc:creator>A Ruchlewska</dc:creator>
                <dc:creator>Cl Mulder</dc:creator>
                <dc:creator>R Smulders</dc:creator>
                <dc:creator>Bj Roosenschoon</dc:creator>
                <dc:creator>G Koopmans</dc:creator>
                <dc:creator>A Wierdsma</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:41</dc:source>
        <dc:date>2009-07-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-41</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>41</prism:startingPage>
        <prism:publicationDate>2009-07-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/40">
        <title>Prevalence of obsessive-compulsive disorder in Turkish university students and assessment of associated factors</title>
        <description>Background:
Many students who begin university at risky periods for OCD development cannot meet the new challenges successfully. They often seek help and apply to the university health center for psychiatric distress. We aimed to determine the prevalence and associated factors of Obsessive Compulsive Disorder (OCD) at students of the Cukurova University in this cross sectional study.
Methods:
This study was performed in the Cukurova University Faculty of Education with a population of 5500 students; the representative sample size for detecting the OCD prevalence was calculated to be 800.  After collecting sociodemographic data, we questioned the students for associated factors of OCD. The General Health Questionnaire-12 (GHQ-12) and Composite International Diagnostic Interview (CIDI, Section K) were used for psychiatric evaluation. Logistic regression analysis was performed to evaluate the linkage between OCD and associated factors.
Results:
A total of 804 university students were included in this study. The GHQ-12-positive students (241 students, 29.9%) were interviewed using Section K of the CIDI (222 students, 27.6%). OCD was diagnosed in 33 (4.2%) students. The Logistic regression analysis of the data showed significant associations between OCD and male gender (p: 0.036), living on government dormitory (p: 0.003), living on students&apos; house/parental house (p: 0.006), having private room in the parental house (p: 0.055) and verbal abuse in the family (p:0.006).
Conclusion:
This study demonstrates a higher prevalence of OCD among a group of university students compared to other prevalence studies of OCD in Turkish society. Furthermore, our findings also suggest relationships between OCD and sociodemographic factors, as well as other environmental stress factors.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/40</link>
                <dc:creator>Elcin Yoldascan</dc:creator>
                <dc:creator>Yarkin Ozenli</dc:creator>
                <dc:creator>Oguz Kutlu</dc:creator>
                <dc:creator>Kenan Topal</dc:creator>
                <dc:creator>Ali Bozkurt</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:40</dc:source>
        <dc:date>2009-07-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-40</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>40</prism:startingPage>
        <prism:publicationDate>2009-07-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/39">
        <title>Insular cortex involvement in declarative memory deficits in patients with post-traumatic stress disorder</title>
        <description>Background:
Neuroimaging studies have proved that hippocampus relate to the deficient of memory in patients with post-traumatic stress disorder (PTSD). Many studies in healthy subjects also shown that insular cortex (IC) be involved in the declarative memory. This study was designed to investigate whether insular cortex is involved in declarative memory deficits in patients with PTSD.
Methods:
Twelve subjects with PTSD and 12 subjects without PTSD victims underwent functional magnetic resonance imaging and magnetic resonance imaging. All subjects performed encoding and retrieval memory tasks during the fMRI session. Voxel-based morphometry method was used to analyze gray-matter volume, and the Statistical Parametric Mapping (SPM2) was used to analyze activated brain areas when performing tasks.
Results:
Grey matter volume was significantly reduced bilaterally in the insular cortex of PTSD subjects than non-PTSD. PTSD group also had lower level of activation in insular cortex when performing word encoding and retrieval tasks than non-PTSD group.
Conclusion:
The study provides evidence on structural and function abnormalities of the insular cortex in patients with PTSD. Reduced grey-matter volume in insular cortex may be associated with declarative memory deficits in patients with PTSD.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/39</link>
                <dc:creator>Shulin Chen</dc:creator>
                <dc:creator>Lingjiang Li</dc:creator>
                <dc:creator>Baihua Xu</dc:creator>
                <dc:creator>Jun Liu</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:39</dc:source>
        <dc:date>2009-06-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-39</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>39</prism:startingPage>
        <prism:publicationDate>2009-06-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/38">
        <title>Persistence and compliance to antidepressant treatment in patients with depression: A chart review</title>
        <description>Background:
Adherence has recently been suggested to be divided into these two components: persistence (i.e., whether patients continue treatment or not) and compliance (i.e., whether patients take doses as instructed). However, no study has yet assessed these two clinically relevant components at the same time in adherence to antidepressant treatment in the clinical outpatient setting.
Methods:
In this retrospective chart-review, 6-month adherence to antidepressants was examined in 367 outpatients with a major depressive disorder (ICD-10) (170 males; mean &#177; SD age 37.6 &#177; 13.9 years), who started antidepressant treatment from April 2006 through March 2007. Additionally, we evaluated Medication Possession Rate (MPR), defined as the total days a medication was dispensed to patients divided by the treatment period.
Results:
Only 161 patients (44.3%) continued antidepressant treatment for 6 months. Among 252 patients who discontinued their initial antidepressant, 63.1% of these patients did so without consulting their physicians. Sertraline use was associated with a higher persistence rate at month 6 (odds ratio 2.59 in comparison with sulpiride), and the use of anxiolytic benzodiazepines had a positive effect on persistence to antidepressant treatment only at month 1 (odds ratio 2.14). An overall MPR was 0.77; 55.6% of patients were considered compliant (i.e., a MPR of &#8805; 0.8).
Conclusion:
Given a high rate of antidepressant discontinuation without consulting their physicians, closer communication between patients and their physicians should be encouraged. Although the use of anxiolytic benzodiazepines was associated with a higher persistence to antidepressant treatment at month 1, the use of these drugs should be avoided as a rule, given their well-known serious adverse effects.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/38</link>
                <dc:creator>Norifusa Sawada</dc:creator>
                <dc:creator>Hiroyuki Uchida</dc:creator>
                <dc:creator>Takefumi Suzuki</dc:creator>
                <dc:creator>Koichiro Watanabe</dc:creator>
                <dc:creator>Toshiaki Kikuchi</dc:creator>
                <dc:creator>Takashi Handa</dc:creator>
                <dc:creator>Haruo Kashima</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:38</dc:source>
        <dc:date>2009-06-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-38</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>38</prism:startingPage>
        <prism:publicationDate>2009-06-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/37">
        <title>Psychotherapy as a treatment modality for psychiatric disorders: Perceptions of general public of Karachi, Pakistan.</title>
        <description>Background:
Psychiatric disorders affect about 450 million individuals worldwide. A number of treatment modalities such as psychotropic medications, psychotherapy and electroconvulsive therapy can be used to treat these disorders. Attitudes of general public play a pivotal role in effective utilization of mental health services. We explored the perceptions of general public of Karachi, Pakistan regarding psychotherapy.
Methods:
A cross-sectional study was conducted in Karachi, Pakistan during July-August, 2008. A three-step sampling strategy and a structured questionnaire were employed to survey knowledge and perceptions of adult general public about psychotherapy. Descriptive statistics were used for baseline characteristics. Logistic regression models were used to investigate any significant associations between baseline characteristics of the participants and their perceptions.
Results:
The study sample comprised of 985 individuals (536 males; 531 financially independent) with an average age of 36.7 years (SD 13.54 years) and 12.5 years (SD 3.09 years) of education were included. Majority (59.4%; n = 585) claimed to be aware of psychotherapy as a treatment option for psychiatric disorders but 47.5% of these (n = 278/585) failed to identify its correct definition. Concerns voiced by the participants about psychotherapy included stigma (48.7%) and breech in confidentiality (39.5%); 60.7% opined it cost effective and 86.5% favored its use as an adjuvant modality. A preference for psychotherapy as the treatment strategy for psychiatric disorders was demonstrated by 46.6% (n = 459/985). Younger, more educated, financially independent and female participants were more likely to prefer psychotherapy as were those who deemed it cost effective.
Conclusion:
Positive attitudes regarding the acceptability, clinical utility and cost-effectiveness of psychotherapy were observed in a sample representative of general public of Karachi, Pakistan. These findings highlight its potential utility for devising pragmatic mental health strategies in the face of limited resources.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/37</link>
                <dc:creator>Abdul Zafar</dc:creator>
                <dc:creator>Ali Jawaid</dc:creator>
                <dc:creator>Hiba Ashraf</dc:creator>
                <dc:creator>Ambreena Fatima</dc:creator>
                <dc:creator>Rubina Anjum</dc:creator>
                <dc:creator>Salah Qureshi</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:37</dc:source>
        <dc:date>2009-06-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-37</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>37</prism:startingPage>
        <prism:publicationDate>2009-06-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/36">
        <title>Study protocol for the development of a European measure of best practice for people with long term mental health problems in institutional care (DEMoBinc)</title>
        <description>Background:
This study aims to build a measure for assessing and reviewing the living conditions, care and human rights of people with longer term mental health problems in psychiatric and social care institutions. Protection of their human rights is imperative since impaired mental capacity secondary to mental illness can make them vulnerable to abuse and exploitation from others. They also constitute a major resource pressure for mental health services, social services, informal carers and society as a whole.Methods/DesignThis study uses an iterative methodology to develop a toolkit to assess internationally agreed domains of care that are considered most important for recovery. These domains are identified by collating results from: i) a systematic review of the literature on institutional care for this service user group; ii) a review of the relevant care standards in each participating country; iii) Delphi exercises in partner countries with mental health professionals, service users, carers and advocates. Common domains and cross-cutting themes are agreed by the principal researchers and an international expert panel. Items are developed to assess these domains and incorporated into the toolkit which is designed to be administered through a face to face interview with the institution&apos;s manager. The toolkit is refined in response to inter-rater reliability testing, feedback from interviewers and interviewees regarding its utility, and feedback from key stakeholders in each country about its ability to deliver information that can be used within each country&apos;s established systems for quality assessment and review. Cross-validation of the toolkit ratings against service users&apos; quality of life, autonomy and markers of recovery tests whether it can deliver a proxy-measure of the service users&apos; experiences of care and the institution&apos;s promotion of their human rights and recovery. The ability of the toolkit to assess the &quot;value for money&quot; delivered by institutions is investigated by comparing toolkit ratings and service costs.DiscussionThe study will deliver the first international tool for the assessment of the quality of institutional care for people with longer term mental health problems that is accurate, reliable, informative, useful and easy to use.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/36</link>
                <dc:creator>Helen Killaspy</dc:creator>
                <dc:creator>Michael King</dc:creator>
                <dc:creator>Christine Wright</dc:creator>
                <dc:creator>Sarah White</dc:creator>
                <dc:creator>Paul McCrone</dc:creator>
                <dc:creator>Thomas Kallert</dc:creator>
                <dc:creator>Jorge Cervilla</dc:creator>
                <dc:creator>Jiri Raboch</dc:creator>
                <dc:creator>Georgi Onchev</dc:creator>
                <dc:creator>Roberto Mezzina</dc:creator>
                <dc:creator>Durk Wiersma</dc:creator>
                <dc:creator>Andzrej Kiejna</dc:creator>
                <dc:creator>Dimitri Ploumpidis</dc:creator>
                <dc:creator>Jose Miguel Caldas de Almeida</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:36</dc:source>
        <dc:date>2009-06-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-36</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2009-06-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/35">
        <title>Psychiatric and psychosocial problems in adults with normal-intelligence autism spectrum disorders</title>
        <description>Background:
Individuals with autism spectrum disorders (ASDs) often display symptoms from other diagnostic categories. Studies of clinical and psychosocial outcome in adult patients with ASDs without concomitant intellectual disability are few. The objective of this paper is to describe the clinical psychiatric presentation and important outcome measures of a large group of normal-intelligence adult patients with ASDs.
Methods:
Autistic symptomatology according to the DSM-IV-criteria and the Gillberg &amp; Gillberg research criteria, patterns of comorbid psychopathology and psychosocial outcome were assessed in 122 consecutively referred adults with normal intelligence ASDs. The subjects consisted of 5 patients with autistic disorder (AD), 67 with Asperger&apos;s disorder (AS) and 50 with pervasive developmental disorder not otherwise specified (PDD NOS). This study group consists of subjects pooled from two studies with highly similar protocols, all seen on an outpatient basis by one of three clinicians.
Results:
Core autistic symptoms were highly prevalent in all ASD subgroups. Though AD subjects had the most pervasive problems, restrictions in non-verbal communication were common across all three subgroups and, contrary to current DSM criteria, so were verbal communication deficits. Lifetime psychiatric axis I comorbidity was very common, most notably mood and anxiety disorders, but also ADHD and psychotic disorders. The frequency of these diagnoses did not differ between the ASD subgroups or between males and females. Antisocial personality disorder and substance abuse were more common in the PDD NOS group. Of all subjects, few led an independent life and very few had ever had a long-term relationship. Female subjects more often reported having been bullied at school than male subjects.
Conclusion:
ASDs are clinical syndromes characterized by impaired social interaction and non-verbal communication in adulthood as well as in childhood. They also carry a high risk for co-existing mental health problems from a broad spectrum of disorders and for unfavourable psychosocial life circumstances. For the next revision of DSM, our findings especially stress the importance of careful examination of the exclusion criterion for adult patients with ASDs.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/35</link>
                <dc:creator>Bjorn Hofvander</dc:creator>
                <dc:creator>Richard Delorme</dc:creator>
                <dc:creator>Pauline Chaste</dc:creator>
                <dc:creator>Agneta Nyden</dc:creator>
                <dc:creator>Elisabet Wentz</dc:creator>
                <dc:creator>Ola Stahlberg</dc:creator>
                <dc:creator>Evelyn Herbrecht</dc:creator>
                <dc:creator>Astrid Stopin</dc:creator>
                <dc:creator>Henrik Anckarsater</dc:creator>
                <dc:creator>Christopher Gillberg</dc:creator>
                <dc:creator>Maria Rastam</dc:creator>
                <dc:creator>Marion Leboyer</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:35</dc:source>
        <dc:date>2009-06-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-35</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2009-06-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/34">
        <title>Violence and post-traumatic stress disorder in Sao Paulo and Rio de Janeiro, Brazil: the protocol for an epidemiological and genetic survey</title>
        <description>Background:
violence is a public health major concern, and it is associated with post-traumatic stress disorder and other psychiatric outcomes. Brazil is one of the most violent countries in the world, and has an extreme social inequality. Research on the association between violence and mental health may support public health policy and thus reduce the burden of disease attributable to violence. The main objectives of this project were: to study the association between violence and mental disorders in the Brazilian population; to estimate the prevalence rates of exposure to violence, post-traumatic stress disorder, common metal disorder, and alcohol hazardous use and dependence: and to identify contextual and individual factors, including genetic factors, associated with the outcomes.Methods/designone phase cross-sectional survey carried out in Sao Paulo and Rio de Janeiro, Brazil. A multistage probability to size sampling scheme was performed in order to select the participants (3000 and 1500 respectively). The cities were stratified according to homicide rates, and in Sao Paulo the three most violent strata were oversampled. The measurements included exposure to traumatic events, psychiatric diagnoses (CIDI 2.1), contextual (homicide rates and social indicators), and individual factors, such as demographics, social capital, resilience, help seeking behaviours. The interviews were carried between June/2007 February/2008, by a team of lay interviewers. The statistical analyses will be weight-adjusted in order to take account of the design effects. Standardization will be used in order to compare the results between the two centres. Whole genome association analysis will be performed on the 1 million SNP (single nucleotide polymorphism) arrays, and additional association analysis will be performed on additional phenotypes. The Ethical Committee of the Federal University of Sao Paulo approved the study, and participants who matched diagnostic criteria have been offered a referral to outpatient clinics at the Federal University of Sao Paulo and Federal University of Rio de Janeiro.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/34</link>
                <dc:creator>Sergio Baxter Andreoli</dc:creator>
                <dc:creator>Wagner Silva Ribeiro</dc:creator>
                <dc:creator>Maria Ines Quintana</dc:creator>
                <dc:creator>Camila Guindalini</dc:creator>
                <dc:creator>Gerome Breen</dc:creator>
                <dc:creator>Sergio Luis Blay</dc:creator>
                <dc:creator>Evandro Coutinho</dc:creator>
                <dc:creator>Trudy Harpham</dc:creator>
                <dc:creator>Miguel Roberto Jorge</dc:creator>
                <dc:creator>Diogo Rizzato Lara</dc:creator>
                <dc:creator>Tais Moriyama</dc:creator>
                <dc:creator>Lucas Quarantini</dc:creator>
                <dc:creator>Ary Gadelha</dc:creator>
                <dc:creator>Liliane Maria Pereira Vilete</dc:creator>
                <dc:creator>Mary Yeh</dc:creator>
                <dc:creator>Martin Prince</dc:creator>
                <dc:creator>Ivan Figueira</dc:creator>
                <dc:creator>Rodrigo Bressan</dc:creator>
                <dc:creator>Marcelo Mello</dc:creator>
                <dc:creator>Michael Dewey</dc:creator>
                <dc:creator>Cleusa Ferri</dc:creator>
                <dc:creator>Jair de Jesus Mari</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:34</dc:source>
        <dc:date>2009-06-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-34</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2009-06-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-244X/9/33">
        <title>Mixed states vs. pure mania in the french sample of the EMBLEM study: results at baseline and 24 months - European Mania in Bipolar Longitudinal Evaluation of Medication  </title>
        <description>Background:
To describe the clinical course and treatment patterns over 24 months of patients experiencing an acute manic/mixed episode within the standard course of care.
Methods:
EMBLEM was a 2-year European prospective, observational study on outcomes of patients experiencing a manic/mixed episode. Adults with bipolar disorder were enrolled within the standard course of care as in/outpatients if they initiated or changed oral medication for treatment of acute mania. After completing 12 weeks of acute phase, patients were assessed every 3&#8211;6 months during the maintenance phase. We present the 24 month results, with subgroup analysis for mixed states (MS) and pure mania (PM). These subgroup analyses are driven by the high proportion of antidepressants prescribed in this cohort.
Results:
In France, 771 patients were eligible for the maintenance phase. 69% of patients completed the follow up over 24 months. The mean age was 45.5 years (sd = 13.6) with 57% of women. 504 (66%) patients were experiencing a PM and 262 (34%) a MS at baseline. The main significant differences in MS vs. PM at baseline were: a higher rate of women, and in the previous 12 months, a higher frequency of episodes (manic/mixed and depressive), more suicide attempts, more rapid cycling, fewer social activities and more work impairment. Over the 24 months of follow-up the MS group had a significantly lower recovery than PM (36% vs. 46%, p = 0.006). Overall, 42% of all patients were started on monotherapy and 58% on combination therapy; of those 35% and 30% respectively remained on their initial medication throughout the 24 months. At baseline, 36% were treated with an antidepressant, this proportion remains high throughout the follow-up period, with a significantly higher rate for MS vs. PM at 24 months (55% vs. 27%, p &lt; 0.001).
Conclusion:
In this large sample, MS occur frequently (34%), they are more severe at baseline and have a worse functional prognosis than PM. Although antidepressants are not recommended in MS and PM, they were frequently prescribed at baseline and are maintained during the 24 months of follow-up.</description>
        <link>http://www.biomedcentral.com/1471-244X/9/33</link>
                <dc:creator>Jean-Michel Azorin</dc:creator>
                <dc:creator>Elodie Aubrun</dc:creator>
                <dc:creator>Jordan Bertsch</dc:creator>
                <dc:creator>Catherine Reed</dc:creator>
                <dc:creator>Stephanie Gerard</dc:creator>
                <dc:creator>Michael Lukasiewicz</dc:creator>
                <dc:source>BMC Psychiatry 2009, 9:33</dc:source>
        <dc:date>2009-06-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-244X-9-33</dc:identifier>
        <prism:publicationName>BMC Psychiatry</prism:publicationName>
        <prism:issn>1471-244X</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>33</prism:startingPage>
        <prism:publicationDate>2009-06-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
